Rule 3.19A.1

### **Appendix 3X**

#### **Initial Director's Interest Notice**

| Information or documents not available now must be given to ASX as soon as available. | Information and |
|---|-----------------|
| documents given to ASX become ASX's property and may be made public.                  |                 |

Introduced 30/9/2001.

| Name of entity | Australian Clinical Labs Limited |
|----------------|----------------------------------|
| ABN            | 94 645 711 128                   |

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director    | Mark Haberlin |
|---------------------|---------------|
| Date of appointment | 28 April 2021 |

## Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Number & class of securities |  |  |
|------------------------------|--|--|
| NIL                          |  |  |
|                              |  |  |
|                              |  |  |
|                              |  |  |
|                              |  |  |
|                              |  |  |

<sup>+</sup> See chapter 19 for defined terms.

# Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

| Name of holder & nature of   | Number & class of Securities |
|--|------------------------------|
| interest  Note: Provide details of the circumstances giving rise to the relevant interest. |                              |
| Osgand Isgand Dty Limited (ACN)  | 25 000 ordinary charos       |
| Osgood Isgood Pty Limited (ACN 609 704 547) as trustee for the                             | 25,000 ordinary shares       |
| Lampard Frankie Super Fund   |                              |
| ( <b>Osgood</b> ) will be the registered   |                              |
| holder of 25,000 ordinary shares in  |                              |
| Australian Clinical Labs Limited   |                              |
| (ACN 645 711 128) (ACL) on and   |                              |
| from 19 May 2021 (Shares). The   |                              |
| Shares are being acquired by   |                              |
| Osgood under the offer for fully   |                              |
| paid ordinary shares in ACL made   |                              |
| pursuant to the prospectus lodged  |                              |
| by ACL and ACL SaleCo Limited  |                              |
| (ACN 648 177 646) with the Australian Securities and                                       |                              |
| Investments Commission on 28   |                              |
| April 2021.  |                              |
| Mark Haberlin is a director of   |                              |
| Osgood Isgood Pty Limited and is a beneficiary of the Lampard Frankie                      |                              |
| Super Fund.  |                              |

#### Part 3 - Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract                                    | N/A |
|---|-----|
| Nature of interest                                    | N/A |
| Name of registered holder (if issued securities)      | N/A |
| No. and class of securities to which interest relates | N/A |

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3X Page 2 11/3/2002